Entera Bio Ltd. ENTX
Entera Bio Ltd. (Nasdaq: ENTX) is an endocrine/women's health drug developer. Its lead program, EB613 (oral PTH(1-34) tablet), is in Phase 2 for Postmenopausal osteoporosis. Its next catalyst on record is EB613: Initiation of Phase 3 registrational program (single ~750-patient placebo-controlled trial) (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: EB613 — Initiation of Phase 3 registrational program (single ~750-patient placebo-controlled trial) (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| EB613 (oral PTH(1-34)) | Postmenopausal osteoporosis | protein/peptide | Phase 2 |
| EB612 (oral long-acting PTH, with OPKO) | Hypoparathyroidism | protein/peptide | Pre-clinical |
| EB618 (oral GLP-1/glucagon OXM, with OPKO) | Obesity and metabolic disorders | protein/peptide | Pre-clinical |
| Oral GLP-2 (with OPKO) | Short bowel syndrome | protein/peptide | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 endocrine/women's health companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.